| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/10/2013 | US20130012561 Estrogen receptor modulators and uses thereof |
| 01/10/2013 | US20130012560 Kinesin inhibitors as cancer therapeutics |
| 01/10/2013 | US20130012557 Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Treatment of Neoplastic Disorders |
| 01/10/2013 | US20130012550 Methods for prognosis and monitoring cancer therapy |
| 01/10/2013 | US20130012548 Deuterium-substituted omega-diphenylurea and derivatives thereof and pharmaceutical compositions comprising the compounds |
| 01/10/2013 | US20130012538 Compositions and methods for the treatment of metabolic disorders |
| 01/10/2013 | US20130012537 3,8-diaminotetrahydroquinoline derivative |
| 01/10/2013 | US20130012536 Modulators of atp-binding cassette transporters |
| 01/10/2013 | US20130012532 Cyclopropanecarboxylic acid derivative |
| 01/10/2013 | US20130012528 Novel derivatives of erlotinib |
| 01/10/2013 | US20130012525 Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
| 01/10/2013 | US20130012519 Biomarker Identifying the Reactivation of STAT3 After Src Inhibition |
| 01/10/2013 | US20130012518 Bicyclic compounds and their uses as dual c-src / jak inhibitors |
| 01/10/2013 | US20130012517 Quinoline and Quinoxaline Derivatives as Kinase Inhibitors |
| 01/10/2013 | US20130012515 Fused Bicyclic Pyridine and Pyrazine Derivatives as Kinase Inhibitors |
| 01/10/2013 | US20130012513 Hedgehog inhibitors |
| 01/10/2013 | US20130012510 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1 and cx3cr1 |
| 01/10/2013 | US20130012507 Substituted pyrrolo-pyrazole derivatives as kinase inhibitors |
| 01/10/2013 | US20130012505 Benzonaphthyridinamines as autotaxin inhibitors |
| 01/10/2013 | US20130012501 Pyrimidinediamine kinase inhibitors |
| 01/10/2013 | US20130012500 Organic compounds |
| 01/10/2013 | US20130012494 Cyclopropyl-fused-1,3-thiazepines as bace1 and/or bace2 inhibitors |
| 01/10/2013 | US20130012490 Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators |
| 01/10/2013 | US20130012489 Morpholinylquinazolines |
| 01/10/2013 | US20130012488 Benzoxepin pi3k inhibitor compounds and methods of use |
| 01/10/2013 | US20130012485 Organic compounds |
| 01/10/2013 | US20130012479 Polymorphs of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride |
| 01/10/2013 | US20130012476 Compounds and compositions as protein kinase inhibitors |
| 01/10/2013 | US20130012473 Combined use of phospholipid and sulfate groups-carrying polysaccharides for inhibiting metastatic spread |
| 01/10/2013 | US20130012467 Bqc-g, a tumor-selective anti-cancer prodrug |
| 01/10/2013 | US20130012466 Colchicine neoglycosides and methods for their synthesis and use |
| 01/10/2013 | US20130012465 Bibw 2992 for use in the treatment of triple negative breast cancer |
| 01/10/2013 | US20130012452 Method for treating brain cancer using a novel tumor suppressor gene and secreted factor |
| 01/10/2013 | US20130012451 Compositions and methods for inhibiting mmp-9-mediated cell migration |
| 01/10/2013 | US20130012450 Virion Derived Protein Nanoparticles For Delivering Diagnostic Or Therapeutic Agents For The Treatment Of Dermatology Related Genetic Diseases |
| 01/10/2013 | US20130012444 Crystalline solvates of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride |
| 01/10/2013 | US20130012437 Lytic peptides having anti-proliferative activity against prostate cancer cells |
| 01/10/2013 | US20130012435 Multivalent fibronectin based scaffold domain proteins |
| 01/10/2013 | US20130012432 Peptides for Treatment of Obesity |
| 01/10/2013 | US20130012426 Virion Derived Protein Nanoparticles For Delivering Diagnostic Or Therapeutic Agents For the Treatment of Psoriasis |
| 01/10/2013 | US20130011903 Thymidine Kinase Mutants and Fusion Proteins Having Thymidine Kinase and Guanylate Kinase Activities |
| 01/10/2013 | US20130011861 Modulators of p-selectin glycoprotein ligand 1 |
| 01/10/2013 | US20130011503 Herbal medicinal composition and extract thereof for inhibiting growth of cancer cells |
| 01/10/2013 | US20130011499 Herbal medicinal composition and extract thereof for inhibiting growth of cancer cells |
| 01/10/2013 | US20130011498 Method of using beta-hydroxy-beta-methylbutyrate for reducing tumor growth rate |
| 01/10/2013 | US20130011497 Method of treatment and screening method |
| 01/10/2013 | US20130011496 Cancer testis antigens as biomarkers in non-small cell lung cancer |
| 01/10/2013 | US20130011485 Magnetic nanomedicine for inhibiting/treating human prostate cancer |
| 01/10/2013 | US20130011482 Dual component medicament delivery system |
| 01/10/2013 | US20130011481 Pyrroloquinolinyl-Pyrrolidine-2,5-Dione Formulations and Methods for Preparing and Using Same |
| 01/10/2013 | US20130011480 Cytotoxic therapy by proton flux modulation |
| 01/10/2013 | US20130011478 Pharmacologically optimized multimodal drug delivery system for nordihydroguiaretic acid (ndga) |
| 01/10/2013 | US20130011477 Stable Pharmaceutical Composition of Imatinib |
| 01/10/2013 | US20130011464 Drug carrier and drug carrier kit for inhibiting fibrosis |
| 01/10/2013 | US20130011445 Polymer-agent conjugates, particles, compositions, and related methods of use |
| 01/10/2013 | US20130011436 Methods and Compositions Containing Fc Fusion Proteins for Enhancing Immune Responses |
| 01/10/2013 | US20130011430 HUMAN CHORIONIC GONADOTROPIN (hCG) BASED VACCINE FOR PREVENTION AND TREATMENT OF CANCER |
| 01/10/2013 | US20130011426 Recombinant Vaccines and Use Thereof |
| 01/10/2013 | US20130011424 Polyepitope constructs and methods for their preparation and use |
| 01/10/2013 | US20130011423 Metalloproteinase oligopeptides and their therapeutic use |
| 01/10/2013 | US20130011422 Tumor Antigens for the Prevention and/or Treatment of Cancer |
| 01/10/2013 | US20130011419 Cross-linkers and their uses |
| 01/10/2013 | US20130011418 Antibody-Drug Conjugates |
| 01/10/2013 | US20130011413 Method and Pharmaceutical Composition for Treatment of Intestinal Disease |
| 01/10/2013 | US20130011411 Methods and compositions for the diagnosis, prognosis, and treatment of cancer |
| 01/10/2013 | US20130011409 Compositions, Kits, and Methods for the Diagnosis, Prognosis, Monitoring, Treatment and Modulation of Post-Transplant Lymphoproliferative Disorders and Hypoxia Associated Angiogenesis Disorders Using Galectin-1 |
| 01/10/2013 | US20130011406 Anti-kit antibodies and uses thereof |
| 01/10/2013 | US20130011405 Antagonist anti-cd40 monoclonal antibodies and methods for their use |
| 01/10/2013 | US20130011402 Compositions and methods for the diagnosis and treatment of tumor |
| 01/10/2013 | US20130011398 Serpin Fusion Polypeptides and Methods of Use Thereof |
| 01/10/2013 | US20130011394 Complexes comprising mhc class i fusion polypeptides and antigen-specific antibodies and methods of use |
| 01/10/2013 | US20130011392 Method for assessing the ability of a patient to respond to or be safely treated by a nucleoside analog based-chemotherapy |
| 01/10/2013 | US20130011386 Active protease-resistant antibody fc mutants |
| 01/10/2013 | US20130011376 Methods for Enhancing Natural Killer Cell Proliferation and Activity |
| 01/10/2013 | US20130011367 Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis |
| 01/10/2013 | US20130011365 Parp inhibitor compounds, compositions and methods of use |
| 01/10/2013 | US20130011342 Surfactant-free, water-free formable composition and breakable foams and their uses |
| 01/10/2013 | US20130011338 Cupredoxin derived transport agents and methods of use thereof |
| 01/10/2013 | US20130011335 Materials and Methods Related to Sodium/Potassium Adenosine Triphosphate and SRC |
| 01/10/2013 | US20130011333 Methods and Compositions for Nanoparticle-Mediated Cancer Cell-Targeted Delivery |
| 01/10/2013 | CA2844144A1 Rna-yy1 interactions |
| 01/10/2013 | CA2841767A1 Cancer antigen |
| 01/10/2013 | CA2841372A1 Agr2 blocking antibody and use thereof |
| 01/10/2013 | CA2840986A1 Treating cancer with hsp90 inhibitory compounds |
| 01/10/2013 | CA2840883A1 Substituted azaheterocycles for the treatment of cancer |
| 01/10/2013 | CA2840754A1 Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer |
| 01/10/2013 | CA2840620A1 Combination therapy |
| 01/10/2013 | CA2840251A1 Combination therapy |
| 01/10/2013 | CA2840221A1 P97-antibody conjugates and methods of use |
| 01/10/2013 | CA2840147A1 Polypeptide variants and uses thereof |
| 01/10/2013 | CA2839972A1 Compositions containing broccoli seeds extract for treating or preventing prostate cancer |
| 01/10/2013 | CA2839942A1 Tumor-targeted drug combretastatin a4 derivatives |
| 01/10/2013 | CA2839727A1 Systems, methods, and formulations for treating cancer |
| 01/10/2013 | CA2839466A1 Method of treating cholangiocarcinoma and apparatus |
| 01/09/2013 | EP2543665A2 Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide free base |
| 01/09/2013 | EP2543659A1 Dendrimers as non-viral vehicles for gene therapy |
| 01/09/2013 | EP2543390A1 Pharmaceutical composition |
| 01/09/2013 | EP2543389A2 Methods and compositions inhibiting a lysyl oxidase (-like) protein for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis |
| 01/09/2013 | EP2543383A1 Macrocyclic compounds and methods of treatment |
| 01/09/2013 | EP2543375A1 Pyrrolo-pyrimidine analogues as inhibitors of bruton's tyrosine kinase |